CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, has been selected for addition to the Russell 2000®, Russell 3000® and Russell Global® Indexes as part of Russell Investments’ quarterly addition of select initial public offering (IPO) companies. Acceleron will join these indexes after the NASDAQ market closes on December 20, 2013.
Help employers find you! Check out all the jobs and post your resume.
